Catalog No.S2156

LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.

Price Stock Quantity  
USD 270 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

LY2886721 Chemical Structure

LY2886721 Chemical Structure
Molecular Weight: 390.41

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

LY2886721 is available in the following compound libraries:

Product Information

  • Compare BACE Inhibitors
    Compare BACE Products
  • Research Area

Product Description

Biological Activity

Description LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.
Targets BACE [1]
In vitro LY2886721 is an oral, small molecule of β-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of β-amyloid and thereby to slow the clinical progression of AD. [1] LY2886721 can also targetγ-secretase to nhibit the synthesis of β-amyloid. [2]
In vivo

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Adru studies, 2012

[2] Townsend M, et al. J Alzheimers Dis, 2011, 24 Suppl 2, 43-52.

Clinical Trial Information( data from, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT01807026 Completed Alzheimer Disease|Healthy Volunteers Eli Lilly and Company March 2013 Phase 1
NCT01775904 Completed Healthy Volunteers Eli Lilly and Company February 2013 Phase 1
NCT01561430 Terminated Alzheimers Disease Eli Lilly and Company March 2012 Phase 1|Phase 2
NCT01534273 Completed Healthy Volunteers Eli Lilly and Company February 2012 Phase 1
NCT01367262 Completed Healthy Subjects Eli Lilly and Company June 2011 Phase 1

view more

Chemical Information

Download LY2886721 SDF
Molecular Weight (MW) 390.41


CAS No. 1262036-50-9
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 9 mg/mL (23.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related BACE Products

Recently Viewed Items

Tags: buy LY2886721 | LY2886721 supplier | purchase LY2886721 | LY2886721 cost | LY2886721 manufacturer | order LY2886721 | LY2886721 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us